Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

PURPOSE: To explore the safety and tolerability of combining two epigenetic drugs: decitabine (a DNA methyltransferase inhibitor) and panobinostat (a histone deacetylase inhibitor), with chemotherapy with temozolomide (an alkylating agent). The purpose of such combination is to evaluate the use of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Chang, Leon-Ferre, Roberto, Laux, Douglas, Deutsch, Jeremy, Smith, Brian J., Frees, Melanie, Milhem, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175037/
https://www.ncbi.nlm.nih.gov/pubmed/25062770
http://dx.doi.org/10.1007/s00280-014-2501-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175037/
https://www.ncbi.nlm.nih.gov/pubmed/25062770
http://dx.doi.org/10.1007/s00280-014-2501-1

Ejemplares similares